Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
CME Group Chairman and CEO Terrence A. Duffy reported the vesting of 62,902 shares of Class A common stock on March 15, 2026. These performance shares were granted in 2022 and vested based on CME Group’s total shareholder return versus the S&P 500 over the period from January 1, 2023 through December 31, 2025.
To cover related tax withholding obligations, Duffy surrendered 27,866 shares back to the company at a reference price of $311.40 per share. After these compensation-related transactions, he directly holds 90,630 shares of CME Group Class A common stock, reflecting a routine equity award and associated tax withholding rather than open-market buying or selling.
CME Group Inc. Chief Transformation Officer Ken Vroman reported routine equity compensation activity. He acquired 7,076 shares of Class A common stock valued at $311.40 per share through the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
On the same date, 3,135 shares at $311.40 per share were surrendered back to the company to cover tax withholding obligations related to this award, rather than sold on the open market. Following these transactions, Vroman directly holds 18,851 shares of CME Group Class A common stock.
CME Group Inc. senior managing director and Chief Commercial Officer Julie Winkler reported compensation-related share activity. She acquired 8,256 shares of Class A common stock at $311.40 per share through the vesting of performance shares granted in 2022, based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding obligations from this award, she surrendered 3,658 shares back to the company, resulting in a net increase of 4,598 shares and direct ownership of 30,110 shares after the transactions.
CME Group senior executive Derek Sammann received a stock award and surrendered shares for taxes. On March 15, 2026, he acquired 8,256 shares of Class A common stock at $311.40 per share from the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
The number of vested shares was based on total shareholder return versus the S&P 500 from January 1, 2023 through December 31, 2025. On the same date, 3,627 shares at $311.40 were surrendered back to the company to cover tax withholding, leaving 13,312 shares held directly. The filing also shows 11,028 shares held indirectly by a trust and 7,022 shares held indirectly by a spouse.
CME Group Inc. President and CFO Lynne Fitzpatrick reported equity compensation activity in the form of vested stock awards. She acquired 5,504 shares of Class A common stock valued at $311.40 per share from performance shares granted in 2022 and earned based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.
Fitzpatrick then surrendered 2,439 shares to the company to satisfy tax withholding obligations on this performance share award and another 76 shares to cover taxes on restricted stock vesting on March 15, 2026. These tax-withholding dispositions were not open-market sales. After these transactions, she directly owned 23,913 shares of CME Group Class A common stock.
CME Group Inc. reported that MD and Chief Accounting Officer Jack J. Tobin received a grant of 608 shares of Class A common stock as a vested performance share award, valued at $311.40 per share. The award reflects performance shares granted in 2022, determined by CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To cover related tax withholding obligations, Tobin surrendered 179 shares back to the company. After these compensation-related transactions, he directly holds 25,409 Class A shares.
CME Group Inc. Chief Information Officer Sunil Cutinho reported routine equity compensation activity. On March 15, 2026, 8,256 shares of Class A common stock vested from a performance share award granted in 2022 under CME Group’s Omnibus Stock Plan at a reference price of $311.40 per share.
The vesting was based on the company’s total shareholder return relative to the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To satisfy tax withholding obligations related to the award, 3,658 shares were surrendered back to the company at the same price, leaving Cutinho with 23,586 directly held shares after these transactions.
CME Group Inc. managing director and chief accounting officer Jack J. Tobin made a bona fide gift of 105 shares of Class A common stock on March 11, 2026. After this charitable transfer, he continues to hold 24,980 shares directly, indicating the gift represents a small portion of his stake.
CME Group Inc. Chief Transformation Officer Ken Vroman reported an open-market sale of Class A common stock. On March 12, 2026, he sold 5,160 shares at a weighted average price of $309.00 per share, with individual trade prices ranging from $308.969 to $309.11. Following this transaction, he directly holds 14,910 CME Group Class A common shares.
CME Group Inc. provides its proxy statement and invites shareholders to the 2026 annual meeting on May 14, 2026. The company highlights record 2025 financial results, including $6.5 billion in revenue, record average daily volume of 28.1 million contracts, and declared more than $4 billion in total dividends, including an aggregate variable dividend of $2.2 billion. The proxy lists voting items: election of 14 Equity directors, ratification of Ernst & Young LLP as auditor, an advisory vote on executive compensation, proposed amendments to eliminate certain Class B director election rights (ITEMS 4–7), and election of Class B directors under ITEM 8. The materials describe board composition, governance practices, risk oversight, compensation highlights, shareholder engagement activities, and other corporate governance disclosures.